Altered gut microbiota composition and metabolism in Parkinson’s disease
Objective: To define changes in gut microbiota composition and metabolism to enable identification of novel therapeutic targets and strategies for disease modification. Background: Multiple cohort…Protective potential of laughter yoga and clapping exercise on stress level and motor functions in Parkinson’s disease patients with type 2 diabetes
Objective: To examine the protective potential of laughter yoga and clapping exercise on blood glucose regulation on stress level and motor functions of PD patients…LRRK2 PROTAC® degrader molecules induce robust biomarker responses in preclinical in vivo pharmacology studies following acute and chronic oral dosing
Objective: Report on the non-clinical in vivo pharmacokinetic and pharmacodynamic biomarker response to PROteolysis TArgeting Chimera (PROTAC®) molecules designed to induce degradation of leucine rich…Development of potent, orally bioavailable, and highly selective LRRK2 PROTAC® degrader molecules as potential disease modifying therapeutics for Parkinson’s disease
Objective: Report on the pharmacological characteristics of small molecule PROteolysis TArgeting Chimera (PROTAC) molecules designed to induce degradation of leucine rich repeat kinase 2 (LRRK2)…Consanguinity is the key player in complexity of Mendelian form of neurodegeneration with brain iron accumulation in Pakistan
Objective: In the current work, we recognized big inbreed Pakistani family with autosomal recessive NBIA containing several affected individuals. Aim of the research work was…Neurologic Music Therapy (NMT) and Non-Invasive Stimulation for Upper Extremity Performance in Patients with Corticobasal Syndrome (CBS)
Objective: To investigate if NMT with or without non-invasive brain stimulation can improve upper limb performance in patients with corticobasal syndrome Background: Previous research suggests…Multiple N-of-1 trials to investigate hypoxia-based treatment in Parkinson’s disease: safety and short-term effects
Objective: In this study, we describe the safety and short-term effects of the first hypoxia-based treatment trial in Parkinson’s disease by deploying a personalized multiple…Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase)
Objective: To describe the safety profile and tolerability of BIA-28-6156 observed during phase 1 clinical trials. Background: BIA-28-6156 is a novel allosteric activator of beta-glucocerebrosidase…Experiences of People with Parkinson’s Disease use of a wearable technology for the management of drooling; qualitative insights from the Cue Band study
Objective: In the Cue Band study, people with Parkinson’s Disease (PwP) are participating in a randomised controlled trial to compare a mobile Application (App) with…Use of a wearable vibration-based device for the treatment of Parkinson’s disease tremor
Objective: To assess the use of a wearable vibration-based device for the treatment of Parkinson’s disease (PD) tremor. Background: PD is a neurodegenerative movement disorder…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »